Dan Schell articles

31. Life Science Leader Chief Editor Invited To Attend Ringing Of NASDAQ Opening Bel 8/7/2013

    Life Science Leader magazine’s Chief Editor, Rob Wright, was invited to attend the NASDAQ opening bell ringing ceremony on Wednesday, August 7, 2013 as a guest of the executive leadership team of NeoStem, a leader in the emerging cellular therapy industry. By Dan Schell

32. Biotech R&D Spending Jumps 5% 9/28/2012

    Research and development (R&D) expenditures in the biotechnology industry grew five percent in 2011, bouncing back after a decline the prior year. According to a new study from BDO USA, LLP, an accounting and consulting organization, on average, biotech companies spent $50 million on R&D in 2011, up from just over $47 million invested in 2010. By Dan Schell

33. The Evolving Role Of Pharmacovigilance 12/11/2011

    New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events. Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug development process. By Dan Schell, Life Science Leader magazine

34. The Pharma Veteran 4/15/2011

    Blockbusters, megamergers, government investigations — Fred Hassan has experienced them all during his nearly 40-year career.

35. Keeping Your Biopharm Ideas Alive 12/7/2010

    It happens to all of us. You’re fresh from a big industry conference — in this case the BIO International Convention in Chicago — and full of new ideas. You’ve held meetings, attended seminars, and networked until your feet ached. Your head is full of new strategies and processes you can’t wait to get back and investigate. But, now comes the real challenge — assimilating all of that information you just digested. Perhaps this special edition of Life Science Leader can help.

36. How Will Outsourcing Affect Your Company In 2010? 12/7/2010

    "Many companies are seeking to lower risk by reducing their focus on innovative medicines. This is not our path. Our strategy is to create value by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients.”

37. There's No Use Fighting It … Change Is Coming 11/7/2010

    It’s a scary time to be an executive in the life sciences sector. No matter if you’re the CEO of a top pharma company or the founder of a new biotech startup, these days it seems there’s always some new policy, trend, or regulation that’s impeding your progress.

38. What's With All The Weed? 10/15/2010

    Never has a cover image generated so much buzz in our office than this month’s feature on GW Pharma.

39. The Need For Real-World Examples 10/7/2010

    If you’re a regular reader of Life Science Leader, you probably know by now that I love getting feedback on our articles.

40. Life Sciences: Now Hiring 9/5/2010

    Hiring employees hasn’t been at the top of life science executives’ to-do lists for quite some time now. But that may be changing, as the economy begins to give slight signs of upward movement.